Trial Profile
A Phase I/II Multicenter Open-label Dose Escalation Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cerebroside-sulfatase (Primary)
- Indications Metachromatic leukodystrophy
- Focus Adverse reactions; First in man
- Acronyms IDEAMLD
- Sponsors Shire
- 23 Dec 2019 Results assessing the pharmacokinetic distribution of TAK-611 were published in the Clinical Pharmacology and Therapeutics
- 31 Jan 2017 Status changed from active, no longer recruiting to completed.
- 13 Apr 2016 Status changed from recruiting to active, no longer recruiting.